Skip to main content
logo
Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
103.00
+1.00 (0.98%)
Jul 30, 2026, 1:30 PM CST

TPE:6919 Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
38.0438.0444.4338.9312.8212.34
Revenue Growth
-6.00%-14.40%14.13%203.68%3.90%19.22%
Gross Profit
26.5226.5230.7627.479.619.23
Operating Income
-725.57-707.22-717.14-513.47-319.62-230.73
Net Income
-284.11-351.92-588.83-488.46-286.16-224.29
Earnings Per Share
-0.18-0.23-0.41-0.39-0.24-0.24
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
4,8894,8609,6693,7121,111594.91
Total Debt
0.75311.8720.4628.6836.78
Net Cash (Debt)
4,8884,8579,6573,6911,083558.13
Net Cash Growth
-48.77%-49.70%161.63%240.96%93.96%-
Net Cash Per Share
3.163.156.752.980.920.61

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-330.5-425.9-522.31-423.94-242.76-110.7
Capital Expenditures
-17.51-16.53-10-8.6-14.16-14.9
Free Cash Flow
-348.01-442.43-532.31-432.54-256.93-125.6
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
69.72%69.72%69.23%70.56%74.94%74.83%
Operating Margin
-1907.45%-1859.31%-1613.95%-1318.88%-2493.17%-1869.95%
Pretax Margin
-746.88%-925.20%-1325.18%-1254.64%-2232.10%-1817.52%
Profit Margin
-746.88%-925.20%-1325.18%-1254.64%-2232.10%-1817.76%
FCF Margin
-914.89%-1163.16%-1197.97%-1111.01%-2004.12%-1017.90%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
32.7764.85----
PS Ratio
4173.336316.212123.71604.64587.23-